Welcome to our dedicated page for Nanoviricides SEC filings (Ticker: NNVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Nanoviricides’ SEC reports can feel like decoding a virology journal—clinical protocols, nanomedicine chemistry, and shifting cash-runway tables all packed into hundreds of pages. If you have ever wondered, “How do I find Nanoviricides insider trading Form 4 transactions before the next data release?” this page removes the guesswork.
Stock Titan’s AI instantly converts every filing—whether it’s a quarterly earnings report 10-Q filing or a surprise 8-K material events explained—into plain-English highlights. Our engine flags funding milestones, patent updates, and pipeline risks so you can move from reading to decision-making in minutes. Real-time alerts push Nanoviricides Form 4 insider transactions real-time to your dashboard, while understanding Nanoviricides SEC documents with AI means no more hunting for that single paragraph about NV-387’s toxicology results.
Here’s what you’ll uncover:
- Nanoviricides annual report 10-K simplified—track R&D spend versus cash on hand.
- Nanoviricides proxy statement executive compensation—see how leadership incentives align with trial progress.
- Nanoviricides earnings report filing analysis—compare quarter-over-quarter pipeline costs and dilution risk.
- Nanoviricides executive stock transactions Form 4 to gauge management confidence.
Every document—from the latest prospectus to the next Nanoviricides 8-K—arrives the moment EDGAR posts it, already distilled by our expert models. Stop digging through dense PDFs; get Nanoviricides SEC filings explained simply and act on insights that matter.
NanoViricides, Inc. is presenting a definitive proxy for a shareholder meeting that includes the election of one Class I director and discusses director and executive compensation principles. The election requires a plurality vote with only "For" or "Withheld" votes counting and broker non-votes having no effect. The document emphasizes tying executive pay to company performance through annual bonuses and long-term awards that consider financial and individual goals and corporate values. It also discloses non-employee director equity holdings: Dr. Jawadekar 41,536, Mr. Rokita 41,009, and Mr. Zucker 39,786.
NanoViricides, Inc. filed an 8-K disclosing several exhibit-level agreements that were furnished with the report. The filing lists extensions of employment agreements for Anil Diwan and Meeta Vyas, with Meeta Vyas’s extension effective
The filing provides the existence and dates of these agreements but contains no financial tables, amounts, or detailed terms in the provided text. The exhibits indicate personnel continuity at the executive level and new or amended financing arrangements secured on
NanoViricides, Inc. (NNVC) is a development-stage biopharmaceutical company focused on nanoviricide antiviral drug candidates and has no commercial products or revenue. The filing discloses a net loss of approximately $9.5 million and net cash used in operating activities of about $8.5 million for the year, cash and cash equivalents of approximately $1.6 million at June 30, 2025, and additional ATM equity sales of about $1.25 million through September 24, 2025. Management states substantial doubt about the company’s ability to continue as a going concern absent additional financing and available credit under a $3.0 million line of credit. The company reports ongoing preclinical and clinical activities for NV-387 (multiple Indications including MPox, ARI/SARI, RSV and COVID formulations), license arrangements with milestone and royalty obligations, and reliance on third-party collaborators for trials, manufacturing and commercialization.
FAQ
What is the current stock price of Nanoviricides (NNVC)?
What is the market cap of Nanoviricides (NNVC)?
